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Abstract
Simvastatin and lovastatin are statins traditionally used for lowering serum cholesterol levels. However, there exists
evidence indicating their potential chemotherapeutic characteristics in cancer. In this study, we used bioinformatic analysis
of publicly available data in order to systematically identify the genes involved in resistance to cytotoxic effects of these two
drugs in the NCI60 cell line panel. We used the pharmacological data available for all the NCI60 cell lines to classify
simvastatin or lovastatin resistant and sensitive cell lines, respectively. Next, we performed whole-genome single marker
case-control association tests for the lovastatin and simvastatin resistant and sensitive cells using their publicly available
Affymetrix 125K SNP genomic data. The results were then evaluated using RNAi methodology. After correction of the p-
values for multiple testing using False Discovery Rate, our results identified three genes (NRP1, COL13A1, MRPS31) and six
genes (EAF2, ANK2, AKAP7, STEAP2, LPIN2, PARVB) associated with resistance to simvastatin and lovastatin, respectively.
Functional validation using RNAi confirmed that silencing of EAF2 expression modulated the response of HCT-116 colon
cancer cells to both statins. In summary, we have successfully utilized the publicly available data on the NCI60 cell lines to
perform whole-genome association studies for simvastatin and lovastatin. Our results indicated genes involved in the
cellular response to these statins and siRNA studies confirmed the role of the EAF2 in response to these drugs in HCT-116
colon cancer cells.
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Introduction
Simvastatin and lovastatin are two statins traditionally used for
lowering serum cholesterol levels. The statins are reversible
inhibitors of the microsomal enzyme HMG-CoA reductase, which
converts HMG-CoA to mevalonate. This is an early rate-limiting
step in cholesterol biosynthesis. In humans, inhibition of HMG-
CoA reductase by statins decreases intracellular cholesterol
biosynthesis, which then leads to transcriptionally upregulated
production of microsomal HMG-CoA reductase and cell surface
LDL receptors. However, simvastatin and lovastatin differ in some
important aspects concerning the degree of metabolism and the
number of active and inactive metabolites [1]. More recently,
statins have gained significant notice as anticancer agents based on
preclinical evidence of their antiproliferative, proapoptotic, anti-
invasive and radiosensitizing properties [2,3,4,5,6]. The role of
statins in cholesterol metabolism can explain their potential
cytotoxic characteristics.
Cholesterol is a key lipid that accumulates in membrane micro-
domains called lipid rafts. Lipid rafts play an important role in
signal transduction that triggers cell growth, survival and many
other processes that are correlated with cancer. Cholesterol
accumulation in tumors has been demonstrated by a number of
studies in the past [7,8,9,10]. Accumulation of cholesterol within
lipid raft micro-domains of the plasma membrane may play a role
in stimulating signal transduction pathways. Freeman and
Solomon (2004) have proposed that increase in cholesterol in
prostate tumor cell membrane, which may result from an increase
in circulating levels or from deregulation of endogenous synthesis,
give rise to the coalescence of the raft domains [7]. This in turn
could have an effect on the segregation of positive regulators of
oncogenic signaling within rafts, while keeping negative regulators
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18306in the fluid mosaic membrane fraction [7]. It was further proposed
that the study of the function of lipid rafts in prostate cancer cells
might provide insight into the role of circulating cholesterol in
malignant growth and on the potential relationship between diet
and aggressive disease. Therefore, characterization of proteins
within cholesterol-rich micro domains may serve to better clarify
the signaling pathways, which will lead to the identification of
novel biomarkers for disease progression and new targets for
cancer therapy.
Variable response to drug treatment, such as resistance, is a
serious health concern. Several factors, such as age and diet, are
implicated in chemotherapeutic resistance by influencing the drug
adsorption, transportation, metabolism, and their physiological
actions. Genetic factors are also involved in drug resistance. For
example, genetic variations that cause alterations in gene function
and expression are implicated in drug resistance [11,12].
Therefore, for an optimal treatment efficacy, we need to know
the genes associated with drug resistance as well as their profiles in
each patient (personalized medicine). In this regard, the NCI60
cell line panel forms a promising tool to discover new cancer
drugs. The NCI60 cell line panel is established from a variety of
tumors in order to identify the compounds that can kill cancer cells
[13]. Thus far, this cell line panel has been exposed to over
100,000 different compounds and the cellular responses in the
form of growth rates have been measured. Using NCI60 cell lines,
L-Asparaginase was identified as effective in killing a subset of
ovarian carcinomas [14]. This panel was also used in the
development of bortezomib for treatment of myeloma [13].
The experimental results obtained on the NCI60 cell lines are
compiled at the Developmental Therapeutics Program (DTP)
website [13]. In addition to pharmacological data mentioned
above, other data for NCI60 cell lines is available at the DTP
website, such as the genotypes of the Affymetrix 125K chip single
nucleotide polymorphisms (SNPs). Affymetrix 125K SNP chip
platform has a dense set of SNPs (,124,000) and is utilized to
identify the genomic regions that are associated with disease
predisposition and variable treatment response. Previously, we
have used the NCI60 cell line data to investigate drug resistance
genes in human genome [15,16,17]. In this study, we took
advantage of both the available pharmacological and genomic
data on the NCI60 cell lines to identify the genes associated with
cytotoxic resistance to simvastatin and lovastatin and performed
functional studies using siRNA to validate EAF2 as a modulator of
statin activity.
Materials and Methods
Lovastatin and simvastatin Resistant and Sensitive NCI60
Cell Lines
We have followed a previously developed approach to perform
the whole-genome case-control association study [15,16,17].
Briefly, we have utilized the publicly available data on the
NCI60 cell line panel posted at the Developmental Therapeutics
Program (DTP) website of NCI/NIH (http://dtp.nci.nih.gov/
index.html). First, we downloaded the GI50 data (the amount of
the drugs required to inhibit growth by 50%) at the 10
24.5 M dose
for the cell lines. Next, we categorized the cells as relatively
resistant or sensitive after normalizing the log10 of GI50 to obtain a
mean of zero and standard deviation of one as previously
described [15,16,17]. The standardized GI50 values were then
analyzed by the SAS 9.1 (PROC UNIVARIATE) with a non-
parametric distribution test (density kernel estimation) with
estimated bandwidths of 0.2476 and 0.2896 as well as asymptotic
mean integrated squared errors (AMISE) of 0.0224 and 0.0172,
for simvastatin and lovastatin, respectively. The visual antimodes
were used as a cut-off value at 20.2 for simvastatin and 20.3 for
lovastatin to define sensitive (controls) and resistant (cases) NCI60
cells (Figure 1). In the case of simvastatin, there were 19 sensitive
and 32 resistant cell lines in the panel (Table S1). There were 16
sensitive and 41 resistant cell lines in the NCI60 panel for
lovastatin (Table S2).
Whole-Genome Case-Control Association Study
We downloaded the Affymetrix 125K SNP data (that had
approximately 124,000 SNPs spaced with a median intermarker
distance of 8.5 kilobases) from the DTP website (http://dtp.nci.
nih.gov/mtargets/download.html) [18]. Whole-genome single
marker case-control association tests for the lovastatin and
simvastatin resistant and sensitive cells was performed by the
PLINK software [19] using the standard chi-square test. Only the
SNPs that have been genotyped in at least 75% of the cells and
had a minimum minor allele frequency of 2% (n=79,622) were
included in this study and were used for the association testing. In
order to decrease the chance for false-positive associations, a
correction for multiple testing, i.e. the False Discovery Rate (FDR)
proposed by Benjamini and Hochberg (FDR_BH) [20] was also
performed by the PLINK software. Results with p values ,0.05
were considered significant.
Information related to genomic locations (genic versus intergenic)
of SNPs were either retrieved from the dbSNP database [21] or by
blasting the SNP-flanking sequences against the human genome
and by visualizing using the NCBI Map Viewer option [22].
Epistasis (SNP-SNP Interaction) Analysis
Logistic regression models were used to analyze two-way
interactions among the SNPs associated individually with
simvastatin or lovastatin resistance, assuming an additive model
for each SNP. For testing SNP-SNP interactions, we used the
likelihood ratio test approach by comparing the fit of two models,
one with the SNP main effects only and the other with the main
effects and two-way interaction effect. The corresponding p-
values were adjusted for multiple testing by the FDR_BH [20]
method.
Cell Culture
The human colon cancer cell lines HCT-116 and HT-29 were
obtained from the American Type Culture Collection (Manassas,
VA). HCT-116 is a tumorigenic colorectal carcinoma cell line
established from a primary tumor [23]. HT-29 is a colon
adenocarcinoma grade II cell line established from primary tumor
cells [24]. Cells were grown in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% FBS, 2 mM L-glutamine,
100 IU/ml penicillin G, and 100 mg/ml streptomycin. All media
reagents were obtained from Invitrogen (Carlsbad, CA). The cell
lines were routinely maintained at 37uC in a humidified 5% CO2
atmosphere.
Functional validation for lovastatin and simvastatin
sensitization
For siRNA and drug studies, cells were transfected with siRNA
by reverse transfection in 384-well plates as previously described
[25]. Briefly, siRNA was printed onto 384-well plates in 2 ml
volume. Diluted siLentFect reagent (BioRad, Hercules, CA) in
OptiMEM (Invitrogen) was added to the wells and allowed to
complex with siRNA for 30 min at room temperature. HCT-116
or HT-29 cells were resuspended in growth media without
antibiotics and added to plates at a final concentration of 1000
GWAS Identifies EAF2 as a Statin Modulator
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24 hours, varying concentrations ranging from 12 nM to 667 mM
of either lovastatin or simvastatin were added to the assay plates
and incubated for an additional 72 hours. Total viable cell
number was determined by the addition of Cell Titer Glo
(Promega, Madison, WI) and relative luminescence units (RLU)
were measured using an EnVision plate reader (Perkin-Elmer,
Wellesley, MA). Drug effect was calculated by dividing the average
of the RLU values for the drug treated wells by the average of the
RLU values for vehicle treated wells. The GI50 values were
determined using GraphPad Prism (GraphPad Software, San
Diego, CA) and values were shown as calculated GI50+/295%
confidence interval. Statistical analysis of the data was done using
two-tailed paired Student’s t test. P,0.05 was considered
significant.
Validation of Gene silencing by Quantitative Real-time
PCR (qPCR)
Total RNA from the cell lines was isolated using Qiagen’s RNEasy
Kit from Qiagen Inc. (Valencia, CA). RNA concentration was
determined using NanoDrop-1000 according to the manufacturer’s
recommendations. iScript cDNA Synthesis Kit from Bio-Rad Inc.
(Hercules, CA) was used to prepare cDNA from 500 ng of each
sample. Relative mRNA expression was measured using TaqMan
Gene Expression Assays from ABI Inc. (Foster City, CA) under
manufacturer’s recommended conditions on the Opticon 2 PCR
System (Bio-Rad Inc., Hercules, CA). Relative quantification of gene
expression was accomplished in triplicate. qPCR reactions were
prepared in 96-well formatted qPCR plates from Bio-Rad (Hercules,
CA). The reactions were prepared in singleplexes, triplicates of each
sample with triplicates of endogenous controls, and non-template
Figure 1. Distribution of NCI60 cell lines with respect to their response to treatment with lovastatin or simvastatin. The density
function showed two major modes for each drug. The visual antimodes were used as a cut-off value at 20.2 for simvastatin and 20.3 for lovastatin to
define sensitive and resistant NCI60 cell lines.
doi:10.1371/journal.pone.0018306.g001
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reference gene, GAPDH, and the relative quantification of the gene
expression changes were analyzed using the DDCt method [26,27].
Results
Genome wide associations studies of the NCI60 panel for
lovastatin and simvastatin response
Using the NCI60 cancer-screening data for simvastatin and
lovastatin, cell lines were categorized as relatively sensitive or
resistant (Figure 1). The results obtained from the whole-genome
case-control association studies for simvastatin and lovastatin are
summarized in Tables 1 and 2, respectively. Eight SNPs were
associated with resistance to simvastatin. These SNPs were located
on chromosomes 8q, 9p (two SNPs), 10p, 10q, 13q (two SNPs) and
14p. Five of the SNPs were located in intergenic regions, whereas
the remaining three SNPs were located in introns of known genes
(Table 3), namely, intron 6 of NRP1 (neurophilin), intron 37 of
COL13A1 (type XIII collagen, alpha 1), and intron 6 of MRPS31
(mitochondrial ribosomal protein S31). Two intergenic SNPs,
rs4129864 and rs1343844 were located very close (7387 base pairs
away from each other), suggesting they were likely to be linked
with each other.
In the case of lovastatin, a total of 25 SNPs were associated with
its resistance. Six of these SNPs were located in known or
predicted genes (Tables 2 and 3): in intron 5 of EAF2 (ELL
associated factor 2), in intron 2 of ANK2 (neural ankyrin 2), in
intron 1 of AKAP7 (protein kinase A anchor protein 7), in intron 4
of LPIN2 (Lipin 2), in intron 2 of STEAP2 (six transmembrane
epithelial antigen of the prostate 2), and in intron 11 of PARVB
(parvin beta).
We further studied a possible SNP-SNP interaction for the
simvastatin and lovastatin resistance SNP sets using logistic
regression analysis and did not detect any statistically significant
genetic interaction assuming additive genetic model after the
FDR_BH adjustments. However, considering the small sample
size, it should also be noted that our study did not have sufficient
Table 3. Summary of the biological processes, molecular functions, and cellular location of the proteins corresponding to the
genes found associated with simvastatin and lovastatin resistance in this study.
Drug
Gene
(Entrez Gene ID) GO Biological Processes GO Molecular Function GO Cellular Component
Simvastatin NRP1 (8829) Axon guidance, cell-cell signaling,
organ morphogenesis, positive
regulation of cell proliferation,
signal transduction
Protein binding, vascular
endothelial growth factor
receptor activity
Membrane fraction
COL13A1 (1305) Cell-cell adhesion, cell-matrix
adhesion, endochondral ossification
Extracellular matrix structural
constituent, heparin binding,
protein binding
Collagen XIII, Plasma membrane
MRPS31 (10240) - - Mitochondrion
Lovastatin EAF2 (55840) - Protein binding -
ANK2 (287) - Protein binding, structural
constituent of cytoskeleton
Actin cytoskeleton, membrane
AKAP7 (9465) Intracellular signaling cascade, ion
transport, protein localization
Protein kinase A binding Apical plasma membrane, lateral plasma
membrane, plasma membrane
STEAP2 (261729) Endocytosis, Golgi to plasma
membrane transport, regulated
secretory pathway, response
to hormone response
Transporter activity Cytosol, early endosome, integral to
Golgi membrane, plasma membrane,
trans-golgi network transport vesicle,
vesicular fraction
LPIN2 (9663) no entry no entry no entry
PARVB (29780) - Protein binding -
Gene IDs are obtained from the Entrez Gene resource.
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) of the NCBI. The biological processes, molecular functions, and cellular component information is obtained from
the Gene Ontology (GO) database [44].
doi:10.1371/journal.pone.0018306.t003
Figure 2. Schematic representation of reversal of drug
resistance upon gene silencing by siRNAs. No biological
relationship between the drug resistance and the genes/SNPs identified
in the GWAS study was previously identified. Therefore, herein we
hypothesize that if the functions of these genes are required for the
resistance to these drugs, then, knocking-down their gene expression
using siRNAs will disrupt the function of the genes, which will reverse
the resistance and make the cells sensitive to these drugs again. (A) The
tumor cell line is resistant upon exposure to drug. (B) Upon treatment
with siRNA to candidate gene targets in addition to drug, we predict
that the tumor cell line would become sensitized to the drug leading to
increased cell death. This model is based on the hypothesis that the
specific gene function is required for the drug resistance.
doi:10.1371/journal.pone.0018306.g002
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18306Figure 3. Effect of EAF2 silencing on response to lovastatin and simvastatin. HCT-116 cells (A & C) and HT-29 cells (B & D) were transfected
with siRNA targeting EAF2 by reverse transfection. At 24 hours, the cells were treated with varying doses of either simvastatin (A & B) or lovastatin (C
& D) ranging from 12 nM to 667 mM. Cell number was determined at 72 hours of drug exposure using Cell Titer Glo. Silencing of EAF2 with specific
siRNA significantly affected the response of HCT-116 cells compared to control non-silencing siRNA (p,0.0002 for both EAF2_1 and EAF2_4 siRNAs
shown by *) at doses 2.7 mM and 8.2 mM.
doi:10.1371/journal.pone.0018306.g003
Figure 4. qPCR validation of gene silencing by EAF2 siRNA. (A) Total RNA was isolated from HCT-116 cells transfected for 48 hours with siRNA
targeting EAF2 (EAF2_1 and EAF2_4), non-silencing siRNA or untreated cells. Relative fold differences in EAF2 mRNA levels compared to untreated
and non-silencing siRNA treated cells are shown. (B) qPCR relative expression analysis of EAF2 in HCT-116 and HT-29 cells shows similar expression.
doi:10.1371/journal.pone.0018306.g004
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Pathway analysis did not identify direct interactions between the
protein products of the genes in the simvastatin or lovastatin lists.
Functional studies identifies EAF2 as a modulator of
lovastatin and simvastatin
In order to test the validity of the positive GWAS results, we
performed functional studies. We focused on the SNPs located in
(intronic regions of) genes involved in simvastatin (3 SNPs) and
lovastatin (6 SNPs) resistance (Tables 1 and 2). An extensive
literature search did not reveal known functional consequences of
these SNPs on gene expression or protein function. Thus, the
direct biological relationships between these SNPs and resistance
to simvastatin and lovastatin remained unknown. However, since
our GWAS results have indicated an association of these genes
with resistance to simvastatin or lovastatin, we hypothesized that
the functions of these genes were somehow associated with drug
resistance. Under this hypothesis, down regulation of the gene
expression reverses the observed resistance and makes these cells
sensitive to these drugs again, resulting in increased cellular
toxicity and death (Figure 2). Therefore, we performed drug
response and gene silencing using RNAi methodology studies on
two colon cancer cell lines HCT-116 and HT-29, which were
selected since they were included in the NCI60 set as well as for
their good transfection efficiency and their response to the two
statins. Based on the DTP drug response data, our analysis
classified HCT-116 as relatively resistant to simvastatin (Table
S1); however, lovastatin data was not available for this cell line.
On the other hand, HT-29 was found to be relatively resistant to
both simvastatin and lovastatin (Tables S1 and S2). Initially,
both cell lines were treated with siRNA targeting genes identified
in our analysis followed by treatment with two low doses of either
simvastatin or lovastatin, which indicated four of the genes,
MRPS31, COL13A, EAF2, AKAP7 as potential modulators of drug
response (Data not shown).
Further drug dose response studies were done using siRNA
duplexes targeting MRPS31 and COL13A, which were associated
with resistance to simvastatin, and EAF2 and AKAP7, which were
associated with resistance to lovastatin. These genes were silenced
by siRNA and treated with varying doses of either simvastatin or
lovastatin ranging from 12 nM to 667 mM. Silencing of MRPS31,
AKAP7 and COL13A did not affect the response to either drug
under the experimental conditions applied (data not shown), while
silencing of EAF2 significantly reduced the GI50 of simvastatin and
lovastatin-treated HCT-116 cells, and thus reduced the resistance
of this cell line to these drugs (Figure 3). For HCT-116 cells
treated with simvastatin and siRNA, the GI50 (with 95%
confidence limits) shifted from 8.6+/20.3 mM for non-silencing
siRNA (negative control) to 2.5+/20.2 mM and 3.3+/20.3 mM
for EAF2_1 and EAF2_4 siRNA, respectively. Similarly, for
HCT-116 cells treated with lovastatin the GI50 shifted from
20.1+/20.9 mM for non-silencing siRNA to 4.3+/20.5 mM and
6.5+/20.5 mM for EAF2_1 and EAF2_4 siRNA, respectively.
Furthermore, efficient siRNA transfection was demonstrated in
both cell lines since the control lethal siRNA reduced viability by
greater than 98% in all assays (Figure S1). However, silencing of
EAF2 did not sensitize HT-29 cells to either simvastatin or
lovastatin (Figure 1). These results suggest that down-regulation
of EAF2 expression can modulate the cellular response to both
cholesterol-lowering drugs in HCT-116 colon cancer cells.
The efficacy of gene silencing by siRNAs EAF2_1 and EAF2_4
was confirmed using the qPCR experiments and is shown in
Figure 4A. Even though HCT-116 cells showed sensitization to
the combination of EAF2 silencing and statin treatment, while
HT-29 cells did not, both cell lines showed similar levels of
expression of EAF2 demonstrating that the difference in response
was not due to difference in basal level of EAF2 expression
(Figure 4B). Moreover, siRNA silencing of EAF2 in both cells
lines had minimal effect on cell viability compared to untreated
controls and the non-silencing siRNA control (Figure 5). Taken
together, this data and the shift in the dose response curves
produced by EAF2 silencing in HCT-116 cells indicate that
silencing EAF2 potentiates the effect of statin induced cytotoxicity.
Discussion
Our study represents the first systematic and whole-genome
based association study for simvastatin and lovastatin, two statins
that are promising candidates as cytotoxic drugs in cancer. In this
study, we took advantage of the freely accessible and comprehen-
sive pharmacological and genetic data on the NCI60 cell line
Figure 5. The effect of EAF2 silencing on cell viability. HCT-116 cells and HT-29 cells (1000 cells/well) were reverse transfected with control
siRNA and EAF2 targeting siRNA. Cell viability was determined at 96 hours using Cell Titer Glo and read for luminescence. Data is represented as
percent viability compared to non siRNA treated cells.
doi:10.1371/journal.pone.0018306.g005
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resistance to simvastatin and lovastatin in the human genome.
Our results demonstrated the association of distinct sets of genes
with resistance to these two drugs. We further functionally
validated one target gene, EAF2, using siRNAs to show that its
expression can modulate the cellular response to these two drugs in
HCT-116 cell line.
A whole-genome SNP-based association study identified three
genes associated with simvastatinresistance(Table 3). One of these
genes, NRP1 encodes for a membrane-bound receptor that has roles
in angiogenesis, axon guidance, cell survival, migration, invasion
and immune response. NRP1 also binds to SEMA3, whose activity
is modulated by lipid rafts [28]. Another gene associated with
simvastatin resistance was COL13A1, which encodes for the alpha
chain of a nonfibrillar collagen located in the plasma membrane.
Although its exact biological role has not been characterized yet,
COL13A1 protein is located in adhesive structures of tissues and is
thought to be involved in cell adhesion, migration and bone
development [29]. Lastly, MRPS31 encodes for a mitochondrial
ribosomal protein that is involved in protein synthesis in
mitochondria and is associated with type I diabetes [30].
In the case of lovastatin resistance, our analysis indicated the
association of six genes (Table 3). One of these genes was EAF2,
which is an androgen-response gene associated with the
transcriptional elongation factor MEN/ELL and it is required
for a variety of cellular functions such as the eye development and
growth suppression and apoptosis induction [31,32]. Recently,
Eaf2 knockout in a mouse model was associated with neoplasia of
the lung, liver and prostate as well as B-cell lymphoma [33].
Interestingly, our results clearly show that silencing of EAF2
decreases the GI50 values of HCT-116 colon cancer cells to not
only lovastatin, but also simvastatin. This effect was not seen in the
other colon cancer cell line HT-29 and this could be due to the
genetic heterogeneity between the two cell lines. Another gene
associated with lovastatin resistance was ANK2, which encodes for
one of the three ankyrins that are involved in localization of
proteins at the membrane. ANK2 is critical for normal heart
function and its mutations are one of the causes of congenital
arrhythmia [34]. AKAP7 encodes for a member of the A-kinase
anchoring protein (AKAP) family that anchors the cAMP-
dependent protein kinase A to specific subcellular compartments
[35]. On the other hand, LPIN2 is one of the three lipin genes.
Lpin 1 is involved in adipose tissue development [36]. Although
the exact biological role of this gene is not known, when mutated,
this gene causes Majeed syndrome, an autoinflammatory disorder
[37]. In addition, STEAP2, which encodes a multi-pass membrane
protein that localizes to the Golgi complex, the plasma membrane,
and the vesicular tubular structures in the cytosol, was also
associated with resistance to lovastatin in our study. Recently a
cupric reductase and ferrireductase role for STEAP2 protein was
reported [38]. This gene is also implicated in prostate cancer [39].
Lastly, PARVB, a member of a focal adhesion protein family [40]
that binds to the integrin-linked kinase [41] was also found
associated with lovastatin resistance. It is interesting to note that
the two lists of genes were vastly different between the two statins,
which are both HMG-CoA reductase inhibitors. However, the two
drugs are not identical and differ in their metabolites [42] and
their cytotoxic effects [43,44], which can explain these results. The
cytotoxic effect mediated by the statins could involve targets other
than HMG-CoA reductase such as the bone morphogenic protein
(BMP) pathway as described by Kodach and colleagues [43].
We performed gene silencing and drug response experiments to
test the validity of our GWAS results. In the case of three genes,
MRPS31, COL13A, and AKAP7, our results did not confirm that
their biological functions are directly related to resistance to
simvastatin and lovastatin under our hypothesis and the
experimental conditions applied. This discrepancy between the
GWAS and functional studies can be explained by the possibility
that these genes may represent false positive results of the GWAS
analysis, or the conditions and the hypothesis applied were not
optimum to detect the expected effects. Alternatively, these SNPs
may be located in a genomic region that affects the function of
distant genes, which cannot be tested using our approach. On the
other hand, our genome wide association indicated the association
of EAF2 marker 1840275 (rs2332056, rs4339143) with resistance
to only lovastatin after correction with FDR. In the case of
simvastatin, this marker was associated with its resistance
(unadjusted p,0.01), however, after correction for multiple testing,
this significance was lost. Yet, our functional assessment using
siRNA showed that silencing of EAF2 was not only capable of
modulating response to lovastatin but also to simvastatin in HCT-
116 colon cancer cell line under the experimental conditions
applied (Figure 3). This discrepancy between the results of
genome wide association study and functional assessment
experiments can be explained either by a false-negative association
of EAF2 marker in simvastatin set, or by utilization of different
experimental conditions (e.g. drug dosage) in our siRNA
experiments. Additionally, our results also showed that EAF2
silencing did not sensitize another colon cancer cell line, HT-29
(which was considered relatively resistant to both simvastatin and
lovastatin), suggesting the presence of a possible heterogeneity in
genetic and molecular mechanisms involved in resistance to
statins. Interestingly, HCT-116 is known to carry a K-RAS
mutation while HT-29 does not [45]. Since the statins are
inhibitors of HMG-CoA reductase that can lead to blocking
farneslyation of K-RAS and thus K-RAS activation, it is possible
that carrying a mutant K-RAS may contribute to making HCT-116
cells more susceptible to the combination of EAF2 silencing and
statin treatment. Further studies will be needed to address this
possibility.
Our classification of both the HT-29 and HCT-116 being
relatively resistant is based on the comparison to all the cell lines in
the NCI60 panel. Previous studies on response to simvastatin and
lovastatin of several of the NCI60 cell lines have been reported.
The HL-60 leukemia cell line was previously found to be relatively
resistant to simvastatin treatment (in a dose-dependent manner)
than its all-trans retinoic acid resistant derivative cell line, HL-60-
R2 [46]. Additionally, Martirosyan et. al. showed that the ovarian
cancer cell line, SKOV-3, when treated with Lovastatin showed a
response, but not as much as other cell lines included in their
studies, suggesting that this cell line is not highly sensitive to
lovastatin treatment under the conditions applied [47], which is in
agreement with our results. Lastly, Kodach et. al. had also
previously showed a dose-dependent cellular response to simvas-
tatin and lovastatin in HT-29 and HCT-116 colon cancer cell lines
[43]. Specifically, their findings suggest that at a low concentra-
tion, both statins increase the cell growth in HT-29, however, at
higher concentrations, both statins reduce the cell growth rate in
this cell line. In the case of HCT-116, the same group also found
that this cell line was responsive to statin treatment at variable
doses. Comparatively, they found that HT-29 was slightly more
resistant to the statins than HCT-116, which is similar to our dose
response data. For our GWAS study of the NCI60 data, these two
cell lines were classified as relatively resistant to simvastatin and
HT-29 was classified as relatively resistant to lovastatin. Therefore,
these studies and our results should be interpreted cautiously, since
the observed statin response may be modified by the experimental
conditions and therefore may not be fully concordant among
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addition, since resistance and sensitivity seems to be determined
based on the comparison with other cell lines (which differs among
the different studies), additional cautions should be exercised in
interpretation of results.
Our data suggests that EAF2 silencing can modulate the
response of the statins in cancer cells such as HCT-116. The effect
of EAF2 silencing shifted the GI50 of the statins in HCT-116 cells
by about 2–3 fold to low mM concentrations. These concentrations
are higher than cholesterol controlling therapeutic plasma levels
for lovastatin, which range from 50–200 nM [48]. However,
higher doses of lovastatin, up to ten fold, have been tolerated for
the treatment of cancer [49]. Further studies, such as in vivo
studies, are needed to assess if EAF2 silencing can modulate statin
response at therapeutic doses.
Conclusion
In conclusion, our results showed that two sets of distinct genes were
associated with resistance to either simvastatin or lovastatin. Although
they are both statins, resistance to them was determined by different
genomic locations/genes. This finding suggests the different mecha-
nisms and biology of resistance to these drugs. Moreover, we
demonstrated that down-regulation in expression of EAF2 could
modulate the response to simvastatin and lovastatin in HCT-116 cells.
Further studies are required to confirm the biological involvement of
EAF2and other genes with simvastatin and lovastatin resistance and to
determine the exact molecular basis of the drug resistance.
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relatively sensitive to simvastatin. The standardized GI50
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Figure S1 Effect of control siRNA treatment on the dose
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